Pedro C Barata

63PUBLICATIONS
328CO-AUTHORS
Molecular targetsCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (63)

|Aug 05, 2026
Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.

|Jul 13, 2026
From Guidelines to Practice: Mainstreaming Germline Testing in Prostate Cancer.

|Jul 01, 2026
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.

|May 28, 2026
EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

|May 21, 2026
Variant allele frequency as a potential marker in response to frontline systemic therapy for patients with locally advanced and metastatic urothelial carcinoma.

|Mar 25, 2026
Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study.

Emmanuel S Antonarakis, Qing Cao, Victoria Catharine

Pageof 11

Frequent Collaborators

13 joint publications

Albert Jang

10 joint publications

Rana R McKay

6 joint publications

Elisabeth I Heath

5 joint publications

Neeraj Agarwal